Answers are grounded in this paper and cite their sources.
Visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis (VL-HLH) is a potentially life-threatening condition caused by an overactive immune response triggered by protozoan parasites belonging to the Leishmania species and transmitted by infected sandies. Given the similarities between the clinical presentation of visceral leishmaniasis and hemophagocytic lymphohistiocytosis, identifying leishmaniasis as the underlying disease demands heightened clinical suspicion. The occurrence of secondary HLH has a great impact on prognosis. VL-HLH incidence is increasing in non-endemic areas where the disease is severe, and mortality rates are high. We report two cases of VL-HLH, presenting at a tertiary care centre in the foothills of Himalaya highlighting the variability in clinical presentation and outcomes despite sharing the same underlying disease. The rst case involved a patient with no notable medical history, presenting with persistent fever, abdominal pain, and signicant weight loss. The second case featured a patient with untreated thyroid carcinoma, exhibiting prolonged fever and an abrupt onset of altered mental state without prior neurological symptoms. Although both cases were ultimately diagnosed with VL-HLH, their clinical trajectories differed signicantly, illustrating the unpredictable nature of this condition. The varied presentations and outcomes of these two cases underline the necessity for healthcare providers to maintain a high index of suspicion for VL-HLH, facilitating early diagnosis and timely intervention to improve patient prognoses.
No takes yet. Share an insight, caveat, or question.
Bansal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: